To evaluate the efficacy of paromomycin for the treatment of symptomatic cryptosporidial enteritis in human immunodeficiency virus-infected adults, we conducted a prospective, randomized, double-blind, placebo-controlled trial before the widespread introduction of highly active antiretroviral therapy (HAART). Seven units under the auspices of the AIDS Clinical Trials Group enrolled 35 adults with CD4 cell counts of р150/mm 3 . Initially, 17 patients received paromomycin (500 mg 4 times daily) and 18 received matching placebo for 21 days. Then all patients received paromomycin (500 mg q.i.d.) for an additional 21 days. Clinical definitions of response were measured by an average number of bowel movements per day in association with concurrent need for antidiarrheal agents that was lower than that before study entry. There was no treatment response during the placebo-controlled phase of the study according to protocol-defined criteria ( ). Three paromomycin recipients (17.6%) versus P p .88 2 placebo recipients (14.3%) responded completely. Rates of combined partial and complete responses in the paromomycin arm (8 out of 17, 47.1%) and the placebo arm (5 out of 14, 35.7%) of the study were also similar ( ). The clinical course of cryptosporidiosis was P p .72 quite variable. Paromomycin was not shown to be more effective than placebo for the treatment of symptomatic cryptosporidial enteritis. However, inadequate statistical power prevents definitive rejection of the usefulness of paromomycin as therapy for this infection.
among American and European patients with AIDS has ranged from 0.8% to 6.6% [4] [5] [6] [7] [8] [9] [10] [11] . Cryptosporidium was found prospectively in 8%-23% cases of diarrhea in patients with AIDS [4, [12] [13] [14] . Before the advent of HAART, most patients with AIDS who had CD4 cell counts of !200/mm 3 had lifelong cryptosporidium infection [15] . There is no approved therapy.
The natural history of cryptosporidiosis in HIV-positive patients is quite variable. Symptoms, when present, can be transient (lasting for !28 days), chronic (lasting for 128 days), or fulminant (110 bowel movements per day with eventual death due to disease) [16] . The volume of diarrhea varies not only among patients but also within a given patient over time. Patients with CD4 cell counts of 1150/mm 3 are more likely to have transient disease [15] . Several agents have been tested as treatment for HIV-positive children and adults. These include letrazuril [17] , spiramycin [5] , diclazuril [18] , azithromycin [19] , roxithromycin [20] , and oral bovine immunoglobulin to Cryptosporidium [21] .
Paromomycin is a nonabsorbable aminoglycoside [22] that has activity against C. parvum in vitro [23] and in animal models at high doses. Several small primarily uncontrolled trials of paromomycin for the treatment of cryptosporidiosis in patients with HIV infection or AIDS have shown efficacy [11, [24] [25] [26] [27] [28] [29] [30] . This agent is indicated for the treatment of intestinal amebiasis and has been widely available by prescription. In clinical practice, paromomycin is commonly used to treat cryptosporidiosis in HIV-positive patients despite a paucity of data from randomized clinical trials.
As a result of these factors, the present clinical trial (AIDS Clinical Trials Group study 192) was undertaken as a doubleblind, placebo-controlled, randomized, crossover study to evaluate the efficacy of paromomycin for the treatment of cryptosporidiosis in HIV-positive patients with CD4 cell counts of р150/mm 3 at a time before the widespread use of HAART.
Methods
Study population. Inclusion criteria were as follows: age у13 years; documented HIV infection; absolute CD4 cell count of р150/mm 3 ; presence of diarrhea defined as 4 stools, loose or watery, per day for at least 4 of the 7 days preceding study entry; Cryptosporidium oocysts documented in 2 stool samples obtained during the 14 days immediately preceding administration of the study drug; Karnofsky score of at least 40; willingness to follow a studyspecified antidiarrheal regimen beginning 5 days before randomization; and serum creatinine level !3 times the upper limit of the laboratory reference range. Patients known to be infected with nonpathogenic protozoans such as Blastocystis hominis or Balantidium coli were eligible for enrollment in the study.
Patients were excluded from the study for the following reasons: hypersensitivity to aminoglycosides; treatment during the 14-day period immediately before study drug administration with any putative anticryptosporidial agent (spiramycin, diclazuril, letrazuril, atovaquone, bovine colostrum, azithromycin, clarithromycin, or octreotide); receipt of paromomycin at a dosage of 11 g/d for у14 days before study enrollment; inability to take medication by mouth; and newly diagnosed infection due to other enteric pathogens (cytomegalovirus, Mycobacterium avium complex, Clostridium difficile, Giardia lamblia, Entamoeba histolytica, Isospora belli, Shigella, Salmonella, Yersinia, Campylobacter, and microsporidia). Patients with known chronic microsporidiosis were ineligible for study enrollment.
Study design and treatment regimen. The study was conducted under the auspices of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases as ACTG protocol 192. The study was performed at 6 sites in the US and 1 site in Puerto Rico. The institutional review board at each institution approved the study, and all patients gave written consent. Patients were enrolled from December 1993 to June 1995 (before the availability of lamivudine or HIV-1 protease inhibitors).
The study was a multicenter, randomized, double-blind outpatient clinical trial designed to compare the safety and efficacy of paromomycin with those of placebo. Patients were randomized to receive either placebo or paromomycin at a dosage of 500 mg q.i.d. for 21 days. Following 21 days of placebo or drug administration, treatment was nonblinded; all patients received paromomycin (500 mg q.i.d.) for 21 days. Following 42 days of the study, patients who failed to have a complete response received 1000 g of paromomycin q.i.d. for 21 days. Patients who had a complete response received an additional 21 days of paromomycin (500 mg q.i.d.). Patients who had a complete or partial response after 9 weeks of study treatment were provided the option of receiving a 16-week maintenance regimen that was nonblinded. This 4-stage design permitted evaluation of paromomycin at 2 different doses and 2 different lengths of treatment, while allowing patients with complete response to continue treatment and patients without complete response to attempt treatment with a higher dose.
Each 500-mg dose of paromomycin sulfate (Humatin; ParkeDavis/Warner-Lambert Company, Ann Arbor, MI) was administered as 2 250-mg capsules or matching placebo. All dose changes or adjustments were made by each study center in a standardized manner. The only antidiarrheal agents allowed for use were diphenoxylate hydrochloride with atropine sulfate, loperamide hydrochloride, or deodorized tincture of opium. Other antidiarrheal agents were prohibited to prevent colloidal binding of paromomycin, which could reduce its efficacy. Patients were encouraged to gradually reduce their use of antidiarrheal medications as stool frequency declined. Adverse events and abnormal results of laboratory testing were graded according to a toxicity rating scale developed by the Division of AIDS, National Institutes of Health.
Study assessments. The primary outcome measure was a clinical definition of response as measured by an average number of bowel movements per day in association with concurrent need for antidiarrheal agents that was lower than that before study entry. The number of bowel movements and the amount of antidiarrheal agents used were recorded in a diary by the patient for the 3 days before each study visit. Patients also reported the frequency and intensity of various gastrointestinal and constitutional symptoms. Definitions of clinical response categories, using measurements that compare the 3 days prior to the study visit with pre-entry data, were as follows: complete response, an average of р3 formed bowel movements per day and no use of antidiarrheal agents; partial response, no increase in the use of antidiarrheal agents and у50% decrease in the average number of daily bowel movements or an average of 4-6 bowel movements per day (representing a 25%-49% decrease in the average number of bowel movements per day); failure, !50% decrease or an increase in the number of bowel movements per day and no change or increase in the use of antidiarrheal agents.
Secondary outcome measures included quantitation of Cryptosporidium oocysts in stool specimens, drug tolerance as defined by the occurrence of dose-limiting toxicity, and changes in weight and abdominal symptoms as reported by the patient. The number of parasites in the stool was rated by using a modification of the Centers for Disease Control and Prevention methods for other parasites: grade 0, no organisms per 22-mm 2 coverslip area; grade 1, rare (2-5 organisms per 22-mm 2 coverslip area); grade 2, few (1 organism per 5-10 high-power fields); grade 3, moderate (1-2 organisms per high-power field to as few as 1 organism per 2-3 highpower fields); and grade 4, many (12 organisms in every high-power field). A baseline CD4 ϩ cell count, serum creatinine level, Karnofsky score, and results of complete physical examination were determined within 14 days of randomization. Stool samples for Cryptosporidium, microsporidia, C. difficile toxin, ova, and parasite examinations and for bacterial culture were obtained within the 7 days before study entry.
Safety was monitored through physical examinations, clinical laboratory tests, and reporting of adverse events. Patients were evaluated at weeks 1, 3, 4, 6, and 9 after study entry. Patients who received the escalated dose of paromomycin were also evaluated at week 7. The evaluation included symptom-directed physical examination, determination of the Karnofsky score, weight recording of adverse events, and semiquantitative examination of stool for Cryptosporidium oocysts. Patients completed a daily gastrointestinal symptom diary every day for the first 3 weeks of the study and for each of the 3 days before the evaluations at weeks 6 and 9. Patients also completed a gastrointestinal symptom summary at the end of weeks 1, 3, 6, and 9. Stool samples for the C. difficile toxin assay were obtained at weeks 3, 6, and 9 from patients who reported у3 bowel movements per day at these time points.
Statistical methods. All statistical analyses were conducted at an a level of .05. Comparisons based on data involving categories of observations (categorical data) were tested via Fisher's exact test. Continuous numerical indices were assessed via nonparametric methods (namely, Wilcoxon's 2-sample test). Treatment differences during weeks 3 and 6, based on the protocol definition of response (thus resulting in analyses of categorical data) were assessed by Fisher's exact test. Further efficacy analyses were based on 2 diarrhea-related indices: the mean number of daily bowel movements (average of the 3 days before each study visit) and the percentage change in average daily bowel movements from baseline (both indices were continuous and thus analyzed by Wilcoxon's 2-sample test).
Treatment response was also assessed according to reduction in grade of oocyst excretion and decreased dependency on antidiarrheal medication. Statistical analyses of the above diarrhearelated indices are based on analysis of covariance methods, which adjust for the strong influence of individual baseline diarrhea levels on patient response. All analyses follow the intent-to-treat principle (i.e., patients were assessed according to their initial treatment assignment, regardless of the treatment that they were receiving at the time of a response evaluation).
On the basis of a calculated planned sample of 54 evaluable patients, the study was designed to detect a 35% difference in efficacy rates between the 2 treatments with 80% power. This difference was expected to be between an estimated 5% rate of response to placebo and a 40% rate of response to paromomycin.
Results
Of the 35 patients enrolled in the trial, 17 patients were randomized to the paromomycin group and 18 were randomized to the placebo group. Thirty-one patients completed the 3-week placebo-controlled phase of the study. Twenty patients completed the protocol-specified observation (10 discontinued treatment before week 25), 10 died, 4 refused further contact, and 1 was withdrawn from the study for use of octreotide. There were no differences in the 2 treatment groups with respect to patterns of study withdrawal ( ). Of the 10 patients who died during P p .604 the study, 6 were randomized to the paromomycin group, and 4 were randomized to the placebo group ( ). Wasting and P p .471 dehydration as a result of severe cryptosporidiosis commonly contributed to the cause of these patients' deaths. Of the 5 patients who discontinued the study for reasons other than protocol completion and death, all were randomized to the placebo group ( ), and 4 withdrew voluntarily because of concern of P p .045 lack of efficacy.
Baseline evaluations. The 2 treatment groups were comparable at baseline (table 1) and did not differ with respect to the clinical characteristics of cryptosporidiosis, such as frequency of daily bowel movements (figure 1), grade of oocyst excretion (figure 2), and use of antidiarrheal medication (figure 3). A trend for placebo recipients to weigh more on average than paromomycin recipients was observed (figure 4; P p ). The 2 groups were similar with respect to patient-reported .052 symptoms such as nausea, vomiting, urgency, and abdominal distention.
Placebo-controlled phase (weeks 1-3).
There was no difference in treatment response according to protocol-defined criteria (  ; table 2 ). Three paromomycin recipients (17.6%) P p .88 responded completely compared with 2 placebo recipients (14.3%). The rates of combined partial and complete responses (47% in the paromomycin arm and 35.7% in the placebo arm) were also not different ( ). P p .72 There was a weak trend favoring paromomycin over placebo with respect to frequency of diarrhea, measured as either the average number of daily bowel movements or the percentage change from baseline (data not shown), decrease in the grade of oocyst excretion, and use of antidiarrheal medications (fig- ures 1-3). The former 2 indices were compared by Wilcoxon's 2-sample test, and the latter 2 indices were compared by Fisher's exact test. Analyses of paired data (comparisons of differences from baseline with those from week 3 or 6) were carried out in the hope of reducing the variance of the response; however, overall, the results were consistent with analyses of data (which were not adjusted for baseline).
Six patients randomized to the paromomycin group and 4 randomized to the placebo group had a grade of oocyst excretion of 0 at week 3. No differences in mean patient weight ( ) or percentage weight gain ( ) compared with P p .93 P p .98 baseline values were seen (figure 4). There was no difference between paromomycin and placebo in terms of patient-reported symptoms, such as nausea ( ), vomiting ( ), ur-P p .22 P p .17 gency ( ), and abdominal pain ( ) or distension
There were persistent differences in incidences of abdominal pain, weight loss, and weakness among paromomycin recipients. The number of paromomycin recipients with toxic effects was slightly higher than that of placebo recipients with toxic effects (6 vs. 3 patients, respectively;
). An elevated P p .456 alkaline phosphatase level was the most frequent toxic effect in paromomycin recipients.
Open-label phase (weeks [4] [5] [6] . There was no difference between the 2 treatments in terms of the protocol-defined response criteria during weeks 4-6 of the open-label phase (  ; table 2 ). Four patients (28.6%) originally random-P p 1.000 ized to the paromomycin arm responded completely, compared with 2 in the placebo arm (15.4%). The rates of combined partial and complete responses were 71.5% for the paromomycin arm and 61.6% for the placebo arm ( ). P p 1.000 Similar to the placebo-controlled phase, there was no dif- ference between the 2 groups with respect to the diarrhearelated indices (figures 1-4), gastrointestinal or constitutional symptoms, or grade of oocyst excretion (table 3) . A persistently higher frequency of elevated alkaline phosphatase was observed among patients originally randomized to the paromomycin arm at week 6.. Differences in response between weeks 3 and 6. When response definitions were compared between week 3 and week 6 on an individual patient basis, it is of interest that response categories changed for some patients in both the paromomycin group and the placebo group. Four patients in both groups who had failures at week 3 had partial or complete responses at week 6. Two patients in both groups who had partial or complete responses at week 3 had failures at week 6 (note that a patient must have made it to week 6 of the study for this comparison to be valid). Response categories did not change for the remaining patients.
Results of intent-to-treat analysis versus observed differences.
Originally, an intent-to-treat analysis was performed that included all randomized patients in both the placebo-controlled and open-label phases of the trial. Analysis of observed differences of the actual number of patients who completed weeks 3 and 6 was also performed. Because the intent-to-treat analysis was identical to the analysis of observed differences with respect to the lack of statistical significance, we chose to report the observed differences (tables 2, 3, and 4 and figures 1-4).
Lack of impact of antiretroviral therapy.
This trial was conducted when nucleoside monotherapy was the predominant form of antiretroviral therapy. Of those patients who received antiretroviral therapy, all were receiving nucleoside monotherapy. Status of antiretroviral therapy did not change during the study from baseline for participants and thus did not appear to influence the outcome of treatment.
Factors associated with diarrhea. The frequency of bowel movements at baseline was associated with the frequency at week 3 ( ). Patients with higher frequencies of diarrhea P ! .0001 at baseline had greater decreases than did patients with lower frequencies of diarrhea at baseline. The baseline CD4 cell count was not significantly associated with diarrhea at baseline or with response. This finding may be due to the observation of very low CD4 cell counts, the small patient sample, and the observed high variability in the presentation of the disease.
Density of Cryptosporidium oocysts as a surrogate marker. A secondary end point in this trial was the usefulness of the grade of excreted Cryptosporidium oocysts as a surrogate marker of treatment response. This end point is an alternative to patientreported frequency of diarrhea as such a marker. The absolute grade of excreted Cryptosporidium oocysts in a patient's stool was not associated with the frequency of bowel movements at baseline or during the study. However, reduction in the grade of oocyst excretion (defined as a decrease in the grade of у2 from the baseline value or eradication of the organism from stool) was significantly associated with a lower frequency of diarrhea during week 3 ( ). This difference did not continue at week 6 P p .05 ( ). During week 6, the mean frequency of diarrhea and P p .50 the percentage change from baseline were virtually identical in the group of patients who had decreases in the grade of oocyst excretion and the group of patients who did not. Even though week 3 results were encouraging, week 6 results fail to support the application of reduction in the grade of oocyst excretion as a surrogate marker of treatment response.
Discussion
The evidence for paromomycin efficacy in the treatment of acute or chronic cryptosporidiosis has been variable. A metaanalysis of data from 11 previously reported paromomycin studies included a total of 300 patients who received paromomycin treatment from 1990 to 1996 [14] . The response definitions, doses, and entry criteria were not uniform. The overall reported response rate was 67% (201 of 300 patients). Relapse data were available for 133 of 201 patients with responses; 77 (58%) relapsed. Considering only patients for whom relapse data were available, an overall success rate of 33% is derived. This is slightly higher than the expected rate of transient disease.
From such an analysis, one could conclude that paromomycin is partially effective.
A prospective, placebo-controlled, double-blind trial of paromomycin for the treatment of AIDS-related cryptosporidiosis in 10 patients was reported in 1994 [30] . Reductions were noted in oocyst concentrations, 24-h oocyst counts, and numbers of stools per 24 h for all patients during the 14-day regimen of paromomycin therapy. The small sample (6 paromomycin recipients and 4 placebo recipients), shorter treatment duration, and the different techniques for evaluating oocyst excretion explain why results from this study were divergent from those obtained in the present study.
Treatment with paromomycin did not appear to result in clinical benefit for the participants in our trial. There was a higher than expected response rate in the placebo arm. The power to detect the clinically meaningful difference of 35% (∼15% in the placebo arm vs. 50% in the paromomycin arm) was only 52%. Thus, one cannot definitively conclude that paromomycin has no usefulness as a treatment for HIV infection-associated cryptosporidiosis. However, the lack of a beneficial effect was seen consistently in indices assessing treatment response such as frequency of diarrhea.
This study was conducted as a randomized, double-blind, placebo-controlled trial to minimize investigator and patient selection bias. The patients had advanced HIV disease as manifested by very low CD4 cell counts. Patients appeared to be equally randomized according to CD4 cell count, age, race, sex, Karnofsky score, antiretroviral use, daily number of bowel movements, grade of oocyst excretion, use of antidiarrheal agents, nausea, vomiting, urgency, abdominal distention, and abdominal pain. Factors that would indirectly reflect a clinical advantage, such as antiretroviral therapy, use of antidiarrheal agents, or change of pill use from baseline were not different between the 2 groups. No advantage was seen for patients who used larger amounts of concomitant antidiarrheal agents.
A 3-week course of paromomycin and a 6-week course of paromomycin were compared to determine the possible benefit of an additional 3 weeks of treatment. However, no benefit was detected, and no other markers of progress in patients' conditions (such as increase in weight and decrease in gastrointestinal symptoms) revealed improvement.
The major limitation of the study is the small number of subjects who were enrolled. The initial goal of 54 evaluable patients was not achieved largely due to the wide availability of paromomycin. Slow enrollment resulted in a decision to close the trial early. The impact of underaccrual was a reduction in the power (the ability to detect differences between treatments with high probability) of the study. An important observation of the study was the variability in clinical presentation among participants as well as the high rate of complete and partial responses among placebo recipients. Such clinical variability was unexpected given the very low median CD4 cell count for the group and clinical experience at the time that the trial was designed. Other investigators have noted such variability for a similar cohort [14, 30] . One group observed spontaneous remission in 29% of patients seen at their institution over a 5-year period [31] . This variability underscores the need for placebo-controlled studies of treatment for cryptosporidiosis in this population.
The design of trials of treatment for AIDS-related cryptosporidiosis should be aided by the experience gained from this trial. Important aspects include the necessity of a placebo-controlled phase, formulation of appropriate response criteria and end points, and patient diary recording and management.
The length of the placebo-controlled period of a future study should be carefully considered. A 6-week course might be superior to a 3-week course to detect benefit of treatment. Attention should be paid to patient attrition and scarcity of available data. In addition, the use of length (128 days) and severity of symptoms as inclusion criteria in future studies may reduce the likelihood of observing spontaneous remission in participating subjects.
Criteria for response based on frequency of bowel movements alone are probably not appropriate, as patients respond differently according to baseline levels of diarrhea. The conditions of populations with severe diarrhea may tend to appear to be improving more substantially than those of populations with moderate or low levels of diarrhea. The use of percentage of change from baseline diarrhea as a clinical parameter also inadequately assesses response. So far, self-reported frequency of bowel movements, by means of daily diaries, is the most viable end point for trials of treatment for diarrhea.
Concomitant use of antidiarrheal agents should not be included in the formulation of response. There was an assumption that use of antidiarrheal agents could influence the number of daily bowel movements that occurred. This was not the case. There was no independent effect of use of antidiarrheal agents on the number of bowel movements; use increased or decreased as the number of bowel movements increased or decreased. No advantage was seen for patients who used larger amounts of concomitant antidiarrheal agents.
A concerted effort in this study to establish the number of oocysts in the stool as a surrogate marker of response was only marginally successful. The use of random diarrhea samples to measure oocyst excretion by grade, while acceptable as a diagnostic test [32, 33] , was not strongly predictive of clinical response. It has been suggested that quantitation for oocysts in a 24-h stool collection may be a more accurate indicator of organism load [34] . The fact that patients who had reduced oocyst excretion had the highest percentage drop in frequency of diarrhea from baseline is encouraging. Further study is needed on the use of microbiological parameters in the assessment of AIDS-related cryptosporidiosis.
The present study was conducted before the availability of lamivudine, HIV protease inhibitors, and HAART. A decrease in the prevalence of intestinal cryptosporidiosis among HIVinfected patients was observed concomitantly with the generalization of the prescription of HIV protease inhibitors in France and greatly affected enrollment in a trial of paromomycin treatment there [35] . Such therapy appears to have an impact on the natural history of cryptosporidiosis and must be taken into account in future studies. If advances in antiretroviral therapy further reduce the incidence of cryptosporidiosis, trials to evaluate therapy will be difficult to complete.
To our knowledge, this study represents the largest placebocontrolled trial of paromomycin as treatment for cryptosporidiosis in HIV-infected persons to date. No beneficial effect of paromomycin over placebo was demonstrated. Use of antidiarrheal agents appeared to have little impact on the severity of diarrhea that was observed. Although one cannot definitively conclude that paromomycin has no usefulness as treatment for HIV-associated cryptosporidiosis, the results from this trial are not encouraging. Proven, effective treatment is still needed.
